- Open Access
"Hypoxia-induced down-regulation of microRNA-449a/b impairs control over targeted SERPINE1 (PAI-1) mRNA - a mechanism involved in SERPINE1 (PAI-1) overexpression"
© Muth et al; licensee BioMed Central Ltd. 2010
- Received: 28 December 2009
- Accepted: 1 April 2010
- Published: 1 April 2010
In damaged organs tissue repair and replacement of cells by connective tissue provokes a response of fibroblasts to cellular stress factors such as hypoxia.
MicroRNAs (miRNA) are small non-coding RNA molecules which bind to their mRNA targets which eventually lead to repression of translation. Whether the response of fibroblasts to stress factors also involves the miRNA system is largely unknown.
By miRNA profiling we identified down-regulation of miRNA-449a/b expression in hypoxic fibroblasts. Specific miRNA inhibitors and mimics showed direct evidence for targeting the serine protease inhibitor (serpin) protein (SERPINE1; plasminogen activator inhibitor-1, PAI-1) by miRNA-449a/b leading to SERPINE1 mRNA and protein up- and down-regulation, respectively. SERPINE1 expression in vivo could be located predominantly in areas of fibrosis and remodeling.
Our study offers serious lines of evidence for a novel hypoxia-dependent mechanism involving hypoxia-induced decrease of clustered miRNA-449a/b, hypoxia-induced amplification of concomitant increase of targeted SERPINE1 (PAI-1) and its overexpression in tissues showing a hypoxic environment.
- Primary Fibroblast
- Primary Human Fibroblast
- miRNA Species
- HiPerfect Transfection Reagent
- Normal Oxygen Concentration
Extracellular matrix (ECM) deposition and fibrotic remodeling in damaged tissues is the principle to regain integrity when affected tissues have no or only limited capability for self-renewal . Damage of tissues and cells can be induced by hypoxia, infections and chronic irritants but has in common that the response to injury is very similar. Mechanisms of reparation will take place after trivial wounding of the skin but are also demonstrable in organ transplantation when the allograft is chronically rejected and compartments lose, step by step, their function due to accumulation of ECM.
While hypoxia can cause damage and tissue destruction, the process of tissue repair and remodeling is also accompanied by low oxygen levels in certain areas causing a stress response of fibroblasts and other cell types involved in tissue remodeling .
Tissue damage leads to accumulation of cytokines and numerous growth factors like members of the transforming growth factor β family (TGF β 1-3) and bone morphogenetic proteins (BMPs) [3–5]. Another set of tissue remodeling factors belong to the family of matrix-metalloproteinases (MMPs) and their inhibitors TIMPs (tissue inhibitors of metalloproteinases), [6, 7]. Comparable with MMPs is the action of plasmin and members of the plasminogen activator urokinase-type (uPA) and -tissue-type (tPA) which mediate proteolysis of ECM components but also activation of latent, inactive MMPs [8, 9]. Their negative regulator serine protease inhibitor (serpin) protein (SERPINE1; plasminogen activator inhibitor-1, PAI-1) is an inhibitor of plasmin action and was shown to be a target of TGFβ-1 which implicates cross-talks between the members of the pro-fibrotic system [10, 11].
The microRNA (miRNA) system controls the fate of mRNA molecules and stands for an important cellular regulatory mechanism. Post-transcriptional regulation of mRNA by the microRNA (miRNA) system is thereby highly conserved among species, including humans, and expression of hundreds of miRNA in tissues and cellular lineages has already been reported . Transcripts of miRNA genes form ~ 100 nucleotide-long hairpin primary miRNA (pri-miRNA) precursors which are subsequently translocated from the nucleus to the cytoplasm. They are further processed to shorter double-stranded premature miRNA (~ 80 nucleotide-long pre-miRNA) and finally to mature/functionally active ~ 20 nucleotide-short miRNA species . A given biologically active miRNA will then be incorporated into the so-called RNA-induced silencing complex (RISC), where binding of mRNA targets by miRNA takes place. Semi-complementary binding of miRNA to the 3'-untranslated region (3'-UTR) of target mRNA results in translational suppression or cleavage of mRNA, respectively . Due to these semi-complementary miRNA-mRNA binding abilities, one miRNA might control several potential mRNA targets and, vice versa, one mRNA might be suppressed by several miRNA species .
One particular miRNA was recently shown to be involved in tissue remodeling and matrix deposition, i.e. exclusive up-regulation of miRNA-21 by fibroblasts was shown to be involved in myocardial fibrosis . The up-regulation of miRNA-21 was suggested to be stress induced what attracted our attention because the stress response of fibroblasts on the miRNA level has yet not been accomplished.
We therefore investigated primary fibroblasts under hypoxic stress, determined the miRNA profile, and screened for designated mRNA targets involved in tissue remodeling and fibrosis development. Lastly, we investigated tissues from kidney transplants showing chronic remodeling for aberrations in miRNA expression and impact on designated SERPINE1 mRNA and protein fate.
Cell lines and culture
Primary human fibroblasts (F-18, dermal origin, kindly provided by Dr. Miriam Wittmann, Faculty of Biological Sciences, University of Leeds, UK) and M15D  were cultured as monolayers in RPMI 1640 containing 10% fetal calf serum (FCS) and 1% antibiotics until subconfluence. Metaphase cytogenetics showed no evidence for clonal aberrations in these primary cell lines.
Hypoxia in cell culture
Cell culture flasks were placed into anaerobic jars for 24 hours (Anaeropack for cell culture, Mitsubishi Gas Chemicals, Tokyo, Japan) to induce hypoxic culture conditions as described [16, 17]. Briefly, the Anaeropack for Cell contains sodium ascorbate as the principal ingredient which absorbs oxygen and generates carbon dioxide by oxidative degradation. Magnesium hydroxide is used as a scavenger for carbon dioxide. These reagents are located in paper sachets and are placed into the jars. Controls were cultured in parallel under normal oxygen concentration of ~ 20%. Viability tests of cells in culture were performed before and after 24 hours by Trypan blue exclusion.
Transfection of fibroblasts with miRNA-449 inhibitors and miRNA-449 mimics
The HiPerfect Transfection Reagent (# 301705, Qiagen, Hilden, Germany) was used for transfection with anti-hsa-miRNA-449a/b Inhibitor (#MIN0001541, target sequence UGG CAG UGU AUU GUU AGC UGG U; #MIN0003327, target sequence AGG CAG UGU AUU GUU AGC UGG C; respectively, both Qiagen, Hilden, Germany) or with Syn-hsa-miRNA-449a/b Mimic (#MSY0001541, target sequence UGG CAG UGU AUU GUU AGC UGG U; #MSY0003327, target sequence AGG CAG UGU AUU GUU AGC UGG C; respectively, both Qiagen, Hilden, Germany). A negative control siRNA (#1027280; Qiagen, Hilden, Germany) was transfected as well. This control has no homology to any mammalian gene. Additionally, primary fibroblasts were treated with the HiPerfect Transfection Reagent only.
Transfection was performed according to the manufacturer's protocol for adherent cells in 6-well plates with 2 different concentrations as follows: miRNA inhibitor 50 nM and 100 nM; miRNA mimic 5 nM and 10 nM, respectively. After transfection cell culture flasks were placed into anaerobic jars for 24 hours. Controls were cultured in parallel under normal oxygen tension.
Human tissue specimens
Condensed data on patients histories and sample type
Systemic Lupus erythematosus
(Interstitial fibrosis, tubular atrophy)
5. II 
Systemic vasculitis (Purpura Schoenlein-Henoch)
(Interstitial fibrosis, tubular atrophy)
5. II 
(Interstitial fibrosis, tubular atrophy)
5. III 
Chronic tubulo-interstitial injury,
evidence for calcineurin
Chronic interstitial nephritis
Interstitial fibrosis, tubular atrophy, vasculopathy)
5. II  **
Systemic Lupus erythematosus
in plot "Control"
The monolayer of 1 culture flask (75 cm2) was suspended in 1 ml TRIZOL Reagent (Invitrogen, Carlsbad, CA, USA) and stored over night at -20°C. The extraction of total RNA was accomplished as instructed by the manufacturer. Total RNA was extracted from FFPE tissues following guanidinium isothiocyanate/Proteinase K-based digestion, and conventional organic extraction using phenol/chloroform as we previously described .
The TaqMan MicroRNA Reverse Transcription Kit (Part No. 4366596, Applied Biosystems, Foster City, CA, USA) and the Megaplex™ RT Primer A (Megaplex™ RT Primers, Human Pool A, Part No. 4399966, Applied Biosystems, Foster City, CA, USA) were used to synthesize complimentary DNA (cDNA) for the TaqMan MicroRNA Array (TaqMan® Human MicroRNA A Array v2.0, Part No. 4398965, Applied Biosystems, Foster City, CA, USA). The final reverse transcription reaction consisted of 3.0 μL 500 ng total RNA and 4.5 μL RT reaction mix. cDNA was synthesized as described in the manual of Run Megaplex™ Pools without pre-amplification (Applied Biosystems, Foster City, CA, USA).
The TaqMan MicroRNA Reverse Transcription Kit (Part No. 4366596, Applied Biosystems, Foster City, CA, USA) was also used to synthesize cDNA for the individual TaqMan MicroRNA Assays (RNU48 Assay ID 001006, RNU49 Assay ID 001005, hsa-miRNA-449a Assay ID 001030, hsa-miRNA-449b Assay ID 001608, Applied Biosystems, Foster City, CA, USA) by using 0.01 μg total RNA. For real-time RT-PCR on the mRNA level the High Capacity cDNA Reverse Transcription Kit (Part No. 4368814, Applied Biosystems, Foster City, CA, USA) was applied by using 1 μg total RNA.
The TaqMan Human MicroRNA A Array v2.0 represents a 384-well format (Part No. 4398965, Applied Biosystems, Foster City, CA, USA). 377 human miRNAs, three endogenous controls and one negative control were included. The array was loaded with a mixture of 450 μL TaqMan Universal PCR Master Mix, No AmpErase UNG (Part No. 4324018, Applied Biosystems, Foster City, CA, USA), 6 μL Megaplex RT product and 444 μL HPLC-H2O. The TaqMan Human MicroRNA A Array was performed on a 7900HT Fast Real-Time PCR system and was recorded by the 7900HT SDS 2.3 software (Applied Biosystems, Foster City, CA, USA). Only miRNA showing at least 3-fold increase or decrease were included in the results section. LDA data of miRNA expression are shown in the additional file 1.
Gene expression profiling by custom made low density arrays
A set of 45 genes related to tissue remodeling and fibrosis and 2 reference genes (RNA-polymerase 2 - POLR2A and β-Glucuronidase - GUSB) was selected for custom made TaqMan Low Density Arrays (LDA; Applied Biosystems, Foster City, CA, USA). Details of the genes spotted on the LDA are shown in the additional file 2. The reference gene Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was declared to be mandatory on LDA according to the distributor but due to the well known up-regulation of GAPDH by hypoxia it was not considered as a reference gene for subsequent relative quantification. The entire gene set was spotted 8-fold (8 × 48) on the 384-well micro fluidic card allowing concomitant investigation of 8 samples per run. The array was loaded with a mixture of 5 μL cDNA, 45 μL HPLC-H2O (J.T. Baker, Phillipsburg, NJ, USA) and 50 μL Universal PCR Master Mix (Part No. 4352042, Applied Biosystems, Foster City, CA, USA). TaqMan low density arrays were performed on a 7900HT Fast Real-Time PCR system and recorded by the 7900HT SDS 2.3 software (Applied Biosystems, Foster City, CA, USA). Only genes showing at least 3-fold up- or down-regulation were included in the results section. LDA data of mRNA expression are shown in the additional file 1.
Re-evaluation of miRNA and mRNA targets
The expression of hsa-miRNA-449a (ID 001030) and hsa-miRNA-449b (ID 001608) along with reference small RNA molecules RNU48 (ID 001006) and RNU49 (ID 001005) was re-evaluated by real-time PCR (TaqMan 7500 Fast Real-Time PCR system, Applied Biosystems). Each reaction consisted of 10 μL TaqMan Universal PCR Master Mix, No AmpErase UNG (Part No. 4324018, Applied Biosystems, Foster City, CA, USA), 1 μL of the invidual TaqMan MicroRNA Assay (Applied Biosystems, Foster City, CA, USA), 4 μL HPLC-H2O (J.T. Baker, Phillipsburg, NJ, USA) and 5 μL cDNA.
The re-evaluation of SERPINE1 mRNA expression was performed with 2 different assays (Hs01126606_m1, Hs00167155_m1, respectively, Applied Biosystems, Foster City, CA, USA) in addition to POLR2A (Hs00172187_m1) and GUSB (Hs99999908_m1) as reference genes in 20 μL reactions containing 10 μL TaqMan Gene Expression Master Mix, 1 μL of the individual TaqMan Gene Expression Assay (both Applied Biosystems), 8 μL pure water, and 1 μL cDNA.
Quantification of real-time PCR data
Recorded CT values were converted into ΔCT values relative to reference genes POLR2A and GUSB for mRNA and RNU48 and RNU49 for microRNA, respectively. The 2-ΔΔCT method  was applied by using Excel 8.0 (Microsoft, Redmond, WA, USA). Results were statistically analyzed and graphically visualized with Prism 5.0 (GraphPad Software, San Diego, CA, USA) by applying the one-way analysis of variance (ANOVA) test followed by Tukey's post-test.
Immunocytochemistry and immunohistochemistry
F-18 and M15D were transfected as described and cultured as monolayers on 4-well chamber slides (Nalge Nunc, Naperville, IL, USA) under hypoxia for 24 hours. Primary human fibroblasts were treated with the HiPerfect Transfection Reagent only and cultured under normal oxygen tension. Fixation was carried out in ice-cold acetone for 10 minutes followed by air-drying and rehydration in PBS. The chamber slides were incubated for 1 h with the mouse monoclonal anti-human SERPINE1 antibody raised against amino acids 1 - 250 of the mature protein (1:50 dilution; TJA6, sc-59636, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). For visualization the ZytoChem Plus HRP Polymer-Kit (Zytomed Systems, Berlin, Germany) and the DAB Substrate Kit High Contrast (Zytomed) were used. Counterstaining was accomplished with haematoxylin.
Immunohistochemistry on human kidney tissue was performed on tissue sections (1 - 2 μm) which were deparaffinised and treated with 3% H2O2 for 10 min. Following pre-treatment in a pressure cooker for retrieval of antigens, sections were incubated for 1 hour with the antibody against SERPINE1. Positive control for SERPINE1 was human placenta tissue and an isotype control monoclonal antibody (1:100 dilution, negative control for mouse IgG1 Ab-1, clone NCG01, DLN-05791, dianova, Hamburg, Germany) was used as negative control in lieu of the primary antibody.
Hypoxia induced down-regulation of miRNA in primary fibroblasts
SERPINE1 is the most up-regulated gene in primary fibroblasts cultured under hypoxic conditions
Target prediction for miRNA-449a/b revealed SERPINE1 mRNA as a candidate
From the hypoxia-induced set of aberrantly expressed genes in fibroblasts (Figure 3) we screened for those potentially targeted by miRNA-449a/b. The TargetScan Database (http://microrna.sanger.ac.uk/targets/v5/, Wellcome Trust Sanger Institute) revealed SERPINE1 as a predicted target for both miRNA-449a and miRNA-449b (additional file 3 A + B).
Hypoxia-driven inhibition and mimicking of miRNA-449 revealed direct targeting of SERPINE1 mRNA in vitro
Inhibition and mimicking of miRNA-449 affected SERPINE1 protein expression in fibroblasts
Chronic allograft remodeling showed the inverse expression of miRNA-449a/b and SERPINE1 expression
Uncontrolled tissue remodeling affects organ function, e.g. leads to dysfunction in transplanted organs. Acute tissue damage and wounding but also consecutive tissue repair and remodeling create a hypoxic environment and provide an appropriate condition for changes in gene expression due to hypoxia-sensitivity . The fibroblast is the leading cell type involved in production of ECM following an adequate stimulus, i.e. one single activated fibroblast is able to induce thousands of pro-collagen molecules per minute . It is the nature of tissue repair and remodeling that numerous factors and environmental conditions act in concert to guide the restoration process such as expression of hypoxia-inducible factors (HIF) and their target genes but also growth factors which induce a pro-fibrotic response . Accordingly, at a glance it appears unlikely that a single aberration is predominantly involved in abnormal tissue remodeling. However, it has recently been shown by a decisive study that overexpression of miRNA-21 in fibroblasts is involved in myocardial fibrosis  suggesting that stress signaling could affect miRNA expression.
We found by miRNA profiling that only 3 out of 377 miRNA subtypes were down-regulated in primary fibroblasts when the stress factor hypoxia was tested. A single miRNA, i.e. the miRNA-184 was up-regulated (data not shown). The profiling showed no notable up-regulation of miRNA-21 in our approach. Previous work in cancer cell lines showed a much stronger affection by hypoxia with numerous miRNA being up- or down-regulated [22, 23]. This difference can be explained by the fact that the basic miRNA profile in carcinoma cells is apparently much more aberrant than in normal cells and furthermore likely to be amplified by additional stress factors such as hypoxia.
We used only Pool A and therefore only 377 miRNA for profiling because trials in our lab using also Pool B showed very low numbers of detectable miRNA in different tissues and cell lines tested.
We selected the clustered miRNA subtypes miRNA-449a/b for confirmatory experiments in hypoxic fibroblasts because this decrease should lead to up-regulation of certain mRNA targets in this setting. Additionally, due to the immediate availability of low-density arrays designed to reveal important players in the pathogenesis of myelofibrosis  we performed gene expression profiling in hypoxic fibroblasts. Among other up-regulated factors involved in ECM synthesis and remodeling including HIF-1α targets LOX, EDN1 and GAPDH, SERPINE1 showed the strongest induction by up to 10-fold.
In the next step we asked if one of these hypoxia-inducible factors could be regulated by miRNA-449a/b. The miRBase Target Database (by using the link for TargetScan) listed SERPINE1 as a putative mRNA target of miRNA-449a/b.
We then tested the functional relationship between SERPINE1 and miRNA-449a/b by transfection of fibroblasts with miRNA-449 inhibitors or the respective mimics. SERPINE1 mRNA strongly increased through miRNA-449 inhibition while miRNA-449 mimics restored to baseline SERPINE1 mRNA levels. Of note, targeting of SERPINE1 mRNA by miRNA-449a/b was only demonstrable when hypoxia was present.
Though an increase of SERPINE1 could easily be explained by induction through HIF-1α the experiments using miRNA-449a/b mimics definitely support our proposed mechanism because these mimics induced a decrease of SERPINE1 mRNA level. Accordingly, labeling of SERPINE1 protein in these cell cultures confirmed a strong SERPINE1 protein expression when miRNA-449a was inhibited. When miRNA-449a was mimicked, almost no staining was demonstrable.
The knowledge on miRNA-449 action in humans is limited. In mice, the miRNA-449 was shown to be involved in the development of the choroid plexus . In a model of post-ischemic regeneration in mice and patients with Duchenne muscular dystrophy miRNA-449 was induced and therefore referred to be a "regenerative miRNA" . So it will be a matter of future efforts to test the dynamics of miRNA-449 expression during ischemia/hypoxia and post-hypoxia conditions, i.e. do miRNA-449a/b increase to normal levels when cells were exposed to normal oxygen levels?
We subsequently transferred the finding of inverse expression of miRNA-449/SERPINE1 to an in vivo setting, i.e. chronic allograft remodeling in kidney transplants. We assumed that initial tissue damage and ongoing tissue remodeling generate an environment with hypoxia, at least in certain areas, which affects miRNA-449 and SERPINE1 expression. Indeed, an inverse expression of miRNA-449a/b and SERPINE1 mRNA expression could be demonstrated in almost all patient samples. Apparently, a case-specific down-regulation of miRNA-449a/b expression must not necessarily correlate with the level of increased SERPINE1 mRNA. Consequently, morphological detection of the miRNA of interest should have been the next step. However, miRNA detection by e.g. in-situ-hybridization is more promising when the target of interest is expressed at considerable high levels what did not hold true for decreased miRNA-449. So we decided to look for the cellular source of SERPINE1 overexpression by immunohistochemistry. Because SERPINE1 mRNA and protein is undetectable in healthy kidney tissue  we selected a kidney with an acute diffuse tubular damage known to express SERPINE1 . Kidney tubuli were labeled for SERPINE1 in a patchy pattern but clearly sparing all other compartments except for rarely stained smooth muscle cells of smaller vessels. By contrast, kidney allografts showed strong SERPINE1 labeling predominantly in activated fibroblasts and smooth muscle cells in areas of fibrotic and vascular remodeling, in atrophic tubuli and in the mesangium of glomeruli. Even though barely demonstrable, some inflammatory cells in the kidney transplants were also SERPINE1 positive.
SERPINE1 is known to be induced in kidney disease including kidney fibrosis and chronic allograft dysfunction [reviewed in . SERPINE1 expression is inducible by numerous stimuli most notably by hypoxia and reactive oxygen species (ROS) themselves. However, in chronic hypoxia HIF-1α is no longer present  and thus can hardly be the inducer of SERPINE1 expression in a chronic remodeling process. TGFβ-1 can induce SERPINE1 expression but is inversely controlled by SERPINE1 via plasmin action . Expression of tumor necrosis factor, driven by inflammation, can induce SERPINE1  but apart from some scattered inflammatory cells inflammation was not the predominant feature in our samples.
Regulation of the SERPINE1 molecule is mainly achieved at the transcriptional level and the gene contains binding sites for several transcription factors such as Smads and HIFs . However, the knowledge on post-transcriptional regulation of SERPINE1 mRNA is sparse. SERPINE1 mRNA contains several AU-rich destabilizing elements in the 3'-UTR suggesting a quick turnover. Interestingly, a recent study used a model of kidney fibrosis in rats to show that angiotensin II is able to stabilize SERPINE1 mRNA via the ubiquitous RNA-binding protein human-antigen R (HuR), .
We present a novel mechanism of post-transcriptional control of SERPINE1 where miRNA-449a/b lost the control over SERPINE1 mRNA through down-regulation under hypoxic conditions. If hypoxia-inducible factors themselves or hypoxia-triggered epigenetic mechanisms such as hypermethylation  interfere with miRNA-449a/b expression is a matter of ongoing investigations.
We conclude that during remodeling of organs and tissues which lack the capability for self-renewal the normally tightly controlled and concerted action of different factors may be affected by aberrantly expressed miRNA species lastly leading to fibrosis development. As shown for hypoxia, decreased miRNA-449a/b contributes to increased SERPINE1 level due to impaired miRNA control of SERPINE1 mRNA fate in vitro and potentially likewise in vivo. This novel mechanism is demonstrable in chronic allograft remodeling of the kidney but probably also in other organ fibrosis and should be considered as a potential target for therapeutic intervention.
The authors are indebted to Ms. Nadine Preiß and Ms. Sabine Schröter for their skilled technical assistance. The grant support by the Deutsche Forschungsgemeinschaft, SFB 738, Project C5 (H.K., O.B.) and by Bundesministerium für Bildung und Forschung - BMBF, IFB-Tx. (O.B., C.J.) is gratefully acknowledged.
- Wynn TA: Cellular and molecular mechanisms of fibrosis. J Pathol. 2008, 214 (2): 199-210. 10.1002/path.2277.PubMedPubMed CentralView ArticleGoogle Scholar
- Lee EY, Xia Y, Kim WS, Kim MH, Kim TH, Kim KJ, Park BS, Sung JH: Hypoxia-enhanced wound-healing function of adipose-derived stem cells: increase in stem cell proliferation and up-regulation of VEGF andbFGF. Wound Repair Regen. 2009, 17 (4): 540-7. 10.1111/j.1524-475X.2009.00499.x.PubMedView ArticleGoogle Scholar
- Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA: Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002, 3 (5): 349-63. 10.1038/nrm809.PubMedView ArticleGoogle Scholar
- Wrighton KH, Lin X, Feng XH: Phospho-control of TGF-beta superfamily signaling. Cell Res. 2009, 19 (1): 8-20. 10.1038/cr.2008.327.PubMedPubMed CentralView ArticleGoogle Scholar
- Hopkins DR, Keles S, Greenspan DS: The bone morphogenetic protein 1/Tolloid-like metalloproteinases. Matrix Biol. 2007, 26 (7): 508-23. 10.1016/j.matbio.2007.05.004.PubMedPubMed CentralView ArticleGoogle Scholar
- Emmert-Buck MR, Roth MJ, Zhuang Z, Campo E, Rozhin J, Sloane BF, Liotta LA: Stetler-Stevenson WG Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am J Pathol. 1994, 145 (6): 1285-90.PubMedPubMed CentralGoogle Scholar
- Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, andbiochemistry. Circ Res. 2003, 92 (8): 827-39. 10.1161/01.RES.0000070112.80711.3D.PubMedView ArticleGoogle Scholar
- Wang H, Zhang Y, Heuckeroth RO: PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA. FEBS Lett. 2007, 581 (16): 3098-104. 10.1016/j.febslet.2007.05.049.PubMedView ArticleGoogle Scholar
- Gaertner R, Jacob MP, Prunier F, Angles-Cano E, Mercadier JJ, Michel JB: The plasminogen-MMP system is more activated in the scar than in viable myocardium 3 months post-MI in the rat. J Mol Cell Cardiol. 2005, 38 (1): 193-204. 10.1016/j.yjmcc.2004.10.017.PubMedView ArticleGoogle Scholar
- Laiho M, Saksela O, Keski-Oja J: Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. J Biol Chem. 1987, 262 (36): 17467-74.PubMedGoogle Scholar
- Wilkins-Port CE, Ye Q, Mazurkiewicz JE, Higgins PJ: TGF-beta1 + EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: role forPAI-1. Cancer Res. 2009, 69 (9): 4081-91. 10.1158/0008-5472.CAN-09-0043.PubMedPubMed CentralView ArticleGoogle Scholar
- Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell. 2009, 136: 215-33. 10.1016/j.cell.2009.01.002.PubMedPubMed CentralView ArticleGoogle Scholar
- Hobert O: Gene regulation by transcription factors andmicroRNAs. Science. 2008, 319: 1785-1786. 10.1126/science.1151651.PubMedView ArticleGoogle Scholar
- Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S: MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling infibroblasts. Nature. 2008, 456 (7224): 980-4. 10.1038/nature07511.PubMedView ArticleGoogle Scholar
- Schönermark MP, Bock O, Büchner A, Steinmeier R, Benbow U, Lenarz T: Quantification of tumor cell invasion using confocal laser scan microscopy. Nat Med. 1997, 3 (10): 1167-71. 10.1038/nm1097-1167.PubMedView ArticleGoogle Scholar
- Mamori S, Asakura T, Ohkawa K, Tajiri H: Survivin expression in early hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic culture condition. World J Gastroenterol. 2007, 13 (40): 5306-11.PubMedPubMed CentralView ArticleGoogle Scholar
- Kamiya T, Kwon AH, Kanemaki T, Matsui T, Uetsuji S, Okumura T, Kamiyama Y: A simplified model of hypoxic injury in primary cultured rat hepatocytes, In Vitro. Cell Dev Biol Anim. 1998, 34: 131-137. 10.1007/s11626-998-0095-9.View ArticleGoogle Scholar
- Bock O, Kreipe H, Lehmann U: One-Step Extraction of RNA from Archival Biopsies. Anal Biochem. 2001, 295: 116-117. 10.1006/abio.2001.5188.PubMedView ArticleGoogle Scholar
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT Method. Methods. 2001, 25: 402-8. 10.1006/meth.2001.1262.PubMedView ArticleGoogle Scholar
- Higgins DF, Kimura K, Iwano M, Haase VH: Hypoxia-inducible factor signaling in the development of tissuefibrosis. Cell Cycle. 2008, 7 (9): 1128-32.PubMedPubMed CentralView ArticleGoogle Scholar
- Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, Fauci AS: Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl AcadSci USA. 1986, 83 (12): 4167-71. 10.1073/pnas.83.12.4167.View ArticleGoogle Scholar
- Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, Calin GA, Ivan M: A microRNA signature of hypoxia. Mol Cell Biol. 2007, 27 (5): 1859-67. 10.1128/MCB.01395-06.PubMedPubMed CentralView ArticleGoogle Scholar
- Guimbellot JS, Erickson SW, Mehta T, Wen H, Page GP, Sorscher EJ, Hong JS: Correlation of microRNA levels during hypoxia with predicted target mRNAs through genome-wide microarray analysis. BMC Med Genomics. 2009, 2: 15-10.1186/1755-8794-2-15.PubMedPubMed CentralView ArticleGoogle Scholar
- Bock O, Muth M, Theophile K, Winter M, Hussein K, Büsche G, Kröger N, Kreipe H: Identification of new target molecules PTK2, TGFBR2 and CD9 overexpressed during advanced bone marrow remodelling in primary myelofibrosis. Br J Haematol. 2009, 146 (5): 510-20. 10.1111/j.1365-2141.2009.07808.x.PubMedView ArticleGoogle Scholar
- Redshaw N, Wheeler G, Hajihosseini MK, Dalmay T: microRNA-449 is a putative regulator of choroid plexus development and function. Brain Res. 2009, 1250: 20-6. 10.1016/j.brainres.2008.11.020.PubMedView ArticleGoogle Scholar
- Greco S, De Simone M, Colussi C, Zaccagnini G, Fasanaro P, Pescatori M, Cardani R, Perbellini R, Isaia E, Sale P, Meola G, Capogrossi MC, Gaetano C, Martelli F: Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. FASEB J. 2009, 23 (10): 3335-46. 10.1096/fj.08-128579.PubMedView ArticleGoogle Scholar
- Xu Y, Hagege J, Mougenot B, Sraer JD, Rønne E, Rondeau E: Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney. Kidney Int. 1996, 50 (6): 2011-9. 10.1038/ki.1996.523.PubMedView ArticleGoogle Scholar
- Pontrelli P, Ranieri E, Ursi M, Ghosh-Choudhury G, Gesualdo L, Paolo Schena F, Grandaliano G: jun-N-terminal kinase regulates thrombin-induced PAI-1 gene expression in proximal tubular epithelial cells. Kidney Int. 2004, 65 (6): 2249-61. 10.1111/j.1523-1755.2004.00644.x.PubMedView ArticleGoogle Scholar
- Ha H, Oh EY, Lee HB: The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol. 2009, 5 (4): 203-11. 10.1038/nrneph.2009.15.PubMedView ArticleGoogle Scholar
- Watson JA, Watson CJ, McCrohan AM, Woodfine K, Tosetto M, McDaid J, Gallagher E, Betts D, Baugh J, O'Sullivan J, Murrell A, Watson RW, McCann A: Generation of an epigenetic signature by chronic hypoxia in prostate cells. Hum Mol Genet. 2009, 18 (19): 3594-604. 10.1093/hmg/ddp307.PubMedView ArticleGoogle Scholar
- Lyons RM, Gentry LE, Purchio AF, Moses HL: Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol. 1990, 110 (4): 1361-7. 10.1083/jcb.110.4.1361.PubMedView ArticleGoogle Scholar
- Sakamoto T, Woodcock-Mitchell J, Marutsuka K, Mitchell JJ, Sobel BE, Fujii S: TNF-alpha and insulin, alone and synergistically, induce plasminogen activator inhibitor-1 expression in adipocytes. Am J Physiol. 1999, 276: C1391-7.PubMedGoogle Scholar
- Doller A, Gauer S, Sobkowiak E, Geiger H, Pfeilschifter J, Eberhardt W: Angiotensin II induces renal plasminogen activator inhibitor-1 and cyclooxygenase-2 expression post-transcriptionally via activation of the mRNA-stabilizing factor human-antigen R. Am J Pathol. 2009, 174 (4): 1252-63. 10.2353/ajpath.2009.080652.PubMedPubMed CentralView ArticleGoogle Scholar
- Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson IW, Glotz D, Iskandar SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, Valente M: Banff 07 classification of renal allograft pathology: updates and futuredirections. Am J Transplant. 2008, 8 (4): 753-60. 10.1111/j.1600-6143.2008.02159.x.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.